Development and pharmacokinetic evaluation of granisetron hydrochloride buccal tablets for optimized chemotherapy-induced nausea and vomiting (CINV) relief
Develops granisetron buccal tablets that enhance nausea relief in chemotherapy, suggesting better treatment adherence.
Key Points
The aim is to develop optimized granisetron buccal tablets to improve performance and bioavailability for relieving chemotherapy-induced nausea and vomiting.
Tablets prepared by direct compression
Optimization using response surface methodology
Drug-excipient compatibility assessed by FT-IR and DSC
Mucoadhesion and drug release kinetics evaluated
Pharmacokinetic evaluation compared with oral tablets
No drug-excipient interactions found
Optimized formulation showed adequate mucoadhesion of 8.25 g
Prolonged release time of approximately 323 min
70.23% drug release at 8 hours
Significantly higher C max and AUC compared to oral tablets